<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="editorial" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Mol. Biosci.</journal-id>
<journal-title>Frontiers in Molecular Biosciences</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Mol. Biosci.</abbrev-journal-title>
<issn pub-type="epub">2296-889X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1089813</article-id>
<article-id pub-id-type="doi">10.3389/fmolb.2022.1089813</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Molecular Biosciences</subject>
<subj-group>
<subject>Editorial</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Editorial: Innovation and transformation of chronic airway diseases</article-title>
<alt-title alt-title-type="left-running-head">Zhao et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmolb.2022.1089813">10.3389/fmolb.2022.1089813</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zhao</surname>
<given-names>Rui</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2126303/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Chen</surname>
<given-names>Yan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/963038/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ma</surname>
<given-names>Yiming</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/1354795/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zou</surname>
<given-names>Chunbin</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/858229/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Jing</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/984635/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Zhihua</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1058037/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Second Xiangya Hospital</institution>, <institution>Central South University</institution>, <addr-line>Changsha</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Division of Pulmonary, Allergy, and Critical Care Medicine</institution>, <institution>Department of Medicine</institution>, <institution>University of Pittsburgh School of Medicine</institution>, <addr-line>Pittsburgh</addr-line>, <addr-line>PA</addr-line>, <country>United States</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Zhongshan Hospital</institution>, <institution>Fudan University</institution>, <addr-line>Shanghai</addr-line>, <country>China</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Second Affiliated Hospital</institution>, <institution>School of Medicine</institution>, <institution>Zhejiang University</institution>, <addr-line>Hangzhou</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/21528/overview">William C. Cho</ext-link>, QEH, Hong Kong SAR, China</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/455090/overview">Yahong Chen</ext-link>, Peking University Third Hospital, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/554658/overview">Zhenyu Liang</ext-link>, Guangzhou Institute of Respiratory Health, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/837463/overview">Feng Li</ext-link>, Shanghai Jiao Tong University, China</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Yan Chen, <email>chenyan99727@csu.edu.cn</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Molecular Diagnostics and Therapeutics, a section of the journal Frontiers in Molecular Biosciences</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>13</day>
<month>12</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>9</volume>
<elocation-id>1089813</elocation-id>
<history>
<date date-type="received">
<day>04</day>
<month>11</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>11</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Zhao, Chen, Ma, Zou, Zhang and Chen.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Zhao, Chen, Ma, Zou, Zhang and Chen</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<related-article id="RA1" journal-id="Front. Mol. Biosci." related-article-type="commentary-article" xlink:href="https://www.frontiersin.org/researchtopic/28255" ext-link-type="uri">Editorial on the Research Topic <article-title>Innovation and transformation of chronic airway diseases </article-title>
</related-article>
<kwd-group>
<kwd>chronic airway disease</kwd>
<kwd>innovation</kwd>
<kwd>sulfur compounds</kwd>
<kwd>screening</kwd>
<kwd>advances</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Chronic airway disease, including chronic obstructive pulmonary disease (COPD), bronchial asthma, bronchiectasis, and other pulmonary disease, is a common respiratory disease worldwide (<xref ref-type="bibr" rid="B3">Soriano et al., 2020</xref>, 8(6), 585&#x2013;596).COPD was the third leading cause of death worldwide, causing the death of 3.23 million people (<xref ref-type="bibr" rid="B4">WHO, 2019</xref>), which has become a huge global burden (<xref ref-type="bibr" rid="B2">Quaderi and Hurst, 2018</xref>, 3, e4). In this context, numerous efforts have been made with the aim of identifying the mechanism of these diseases, exploring effective prevention measures and therapeutic strategies. In particular, innovation and transformation of chronic airway diseases should be worthy of attention. To date, the mechanism of chronic airway disease is not completely understood (<xref ref-type="bibr" rid="B1">Barnes Peter, 2017</xref>). Nonetheless, diverse researches have shown great advances, which may bring more efficient therapy of these diseases. Despite this, more innovation is necessary for us to solve the problems in treatment and prevention of chronic airway diseases. This Research Topic aims to collect innovation and transformation research in fields related to the pathogenesis and treatment of chronic airway diseases, to provide new alternatives for early diagnosis and treatment of chronic airway diseases. In this Research Topic, <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fmolb.2022.927549/full">Qiao et al.</ext-link> reviewed the regulator roles of the lncRNA &#x2013; miRNA &#x2013; mRNA network in different cell types and their potential as the biomarkers or therapeutic targets of chronic inflammatory airway diseases (<ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fmolb.2022.927549/full">Qiao et al.</ext-link>). Several lncRNAs acting as miRNA sponges in different cells, such as bronchial epithelial cells, pulmonary microvascular endothelial cells and T Lymphocytes, have been focused in chronic airway diseases. The cross-talk among lncRNAs, miRNAs and mRNAs is involved in the pathophysiology of chronic inflammatory airway diseases. Meanwhile, <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fmolb.2022.928287/full">Jiang and Chen</ext-link> summarized and analyzed the biological functions and mechanisms of sulfur compounds in regulating COPD and its comorbidities (<ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fmolb.2022.928287/full">Jiang and Chen</ext-link>). Sulfur compounds have the potential to protect individuals from developing chronic inflammatory diseases due to their antioxidant and anti-inflammation capabilities. The effect of these sulfur compounds on the development and treatment of COPD discussed in this review. Similarly, <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fmolb.2022.828766/full">Lin et al.</ext-link> assessed endoplasmic reticulum (ER) stress markers, Epithelial mesenchymal transition (EMT) markers and associated signal molecules in rat lungs, bronchial epithelial cells, and human peripheral lung tissues to investigate the effect of H<sub>2</sub>S in regulating EMT and the underlying mechanisms (<ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fmolb.2022.828766/full">Lin et al.</ext-link>). They found that H<sub>2</sub>S inhibits cigarette smoke (CS)- or nicotine- induced ER stress and EMT in bronchial epithelial cells and alleviates CS-induced lung tissue damage and small airway fibrosis. The research suggested endogenous H<sub>2</sub>S may have an inhibitory effect on EMT related small airway fibrosis through regulating ER stress. The inositol-requiring enzyme 1 (IRE1) signal pathway and its downstream signal molecule p-Smad2/3 may be responsible for the inhibitory effect of H<sub>2</sub>S. On the other hand, <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fmolb.2022.839259/full">Huang et al.</ext-link> performed untargeted metabolomics analysis of lung tissue and plasma sample, characterized the metabolic profile of lung tissue from COPD patients and found that glycerophospholipids (GPs) and amino acids metabolism disorder in male COPD patients. GPs may be related to COPD by participating in oxidative stress and inflammation (<ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fmolb.2022.839259/full">Huang et al.</ext-link>). <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fmolb.2022.839259/full">Huang et al.</ext-link> screened and validated differential metabolites associated with male COPD and disordered metabolic pathways. They screened two two overlapping metabolites, phytosphingosine and L-tryptophan, as new promising biomarkers, could be two indicators for early screening of COPD patients. <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fmolb.2022.925700/full">Zhang et al.</ext-link> investigated the effect of glycyl -L histidyl - L-lysine-Cu2&#x2b;(GHK-Cu) on emphysema induced by CS (<ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fmolb.2022.925700/full">Zhang et al.</ext-link>). GHK-Cu treatment attenuated the CS-induced emphysematous changes and partially reversed the matrix metalloprotein -9 (MMP-9)/tissue inhibitor of metalloproteinases-1 (TIMP-1) imbalance in the lung tissue. They found that GHK-Cu provides potential protection against oxidative stress and inflammation induced by CS exposure the protective effects are likely related to modulation of the NF-&#x3ba;B and Nrf2/Keap1 pathways. This report is the first to stress the role of GHK-Cu in an animal model of CS-induced emphysema. GHK-Cu might be a therapeutic candidate for COPD with the role of anti-inflammation and anti-oxidation.</p>
<p>In summary, lots of studies in this Research Topic discuss the mechanism of chronic airway diseases and demonstrate innovative targets and biomarkers. The Research Topic reports the regulator roles of different biomolecules in chronic airway diseases, provides potential treatment and prevention ideas. The innovation and transformation of chronic airway diseases deserve more attention.</p>
</body>
<back>
<sec id="s1">
<title>Author contributions</title>
<p>All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.</p>
</sec>
<ack>
<p>The authors are thankful to the contributors to this Research Topic as well as the Editorial support of the Journal.</p>
</ack>
<sec sec-type="COI-statement" id="s2">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s3">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barnes Peter</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Cellular and molecular mechanisms of asthma and COPD</article-title>. <source>Clin. Sci.</source> <volume>131</volume> (<issue>13</issue>), <fpage>1541</fpage>&#x2013;<lpage>1558</lpage>. <pub-id pub-id-type="doi">10.1042/CS20160487</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quaderi</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Hurst</surname>
<given-names>J. R.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>The unmet global burden of COPD</article-title>. <source>Glob. Health Epidemiol. Genom.</source> <volume>3</volume>, <fpage>e4</fpage>. <pub-id pub-id-type="doi">10.1017/gheg.2018.1</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soriano</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Kendrick</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Paulson</surname>
<given-names>K. R.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Abrams</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Adedoyin</surname>
<given-names>R. A.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Prevalence and attributable Health burden of chronic respiratory diseases, 1990&#x2013;2017: A systematic analysis for the global burden of disease study 2017</article-title>. <source>Lan. Respir. Med.</source> <volume>8</volume> (<issue>6</issue>), <fpage>585</fpage>&#x2013;<lpage>596</lpage>.</citation>
</ref>
<ref id="B4">
<citation citation-type="book">
<collab>WHO</collab> (<year>2019</year>). <source>Global health estimates: Leading causes of death. Cause-Specific mortality 2000&#x2013;2019</source>. <comment>Availableat: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/data/gho/data/themes/mortality-and-global-health-%20estimates/ghe-leading-causes-of-death">https://www.who.int/data/gho/data/themes/mortality-and-global-health- estimates/ghe-leading-causes-of-death</ext-link> (Accessed Sept 30th, 2022)</comment>.</citation>
</ref>
</ref-list>
</back>
</article>